Data from: Pre- and post- treatment fold change plasma proteomics in metastatic NSCLC patients
Data files
Feb 11, 2024 version files 1.18 MB
-
README.md
1.42 KB
-
T0-T1_paper_fc_data_public.csv
1.18 MB
Abstract
Blood plasma samples were collected from advanced-stage NSCLC patients as part of a clinical study (PROPHETIC; NCT04056247). All clinical sites received IRB approval for the study protocol. Patient blood samples were drawn at baseline (referred to as T0) and, on average, 4 weeks after the treatment commenced, prior to the second dose of treatment (referred to as T1). Blood samples were drawn into tubes containing EDTA as an anticoagulant, and plasma was separated from the whole blood. The protocol adheres to the Clinical and Laboratory Standards Institute (CLSI) guidelines.
README: Pre- and Post- treatment fold change plasma proteomics in metastatic NSCLC patients
https://doi.org/10.5061/dryad.98sf7m0rc
This dataset contains fold-change values representing the ratio between on-treatment (T1) and pre-treatment (T0) plasma protein abundance levels in 225 non-small cell lung cancer (NSCLC) patients.
The dataset was used to characterize early on-treatment proteomic changes in blood plasma and gain insights into treatment response and resistance in NSCLC patients treated with immunotherapy.
Description of the data and file structure
The dataset consists of the following file:
fold_change.csv: Fold-change values representing the ratio of on-treatment (T1) to pre-treatment (T0) reads for each aptamer ID, which corresponds to a specific protein. Details regarding the measured proteins according to the aptamer ID are available at Somalogic website (https://menu.somalogic.com/). The fold_change.csv file contains fold-change values for each protein, with rows representing individual patients and columns representing the fold-change ratios for each protein.
Sharing/Access information
Additional details about patient recruitment, sample collection, and data analysis can be found in the accompanying paper titled "Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy" (doi: https://10.3389/fimmu.2024.1364473).